Envoy Medical Inc. is expected to report a Q2 2026 consensus loss of $0.09 per share on revenue of $0.06 million, with its current $0.66 stock price trading significantly below the average analyst price target of $2.50.
Investors are primarily focused on the regulatory progress of the Acclaim fully implanted cochlear implant, specifically the status of the modular Premarket Approval (PMA) submission to the FDA.
The company recently announced a major milestone, surpassing the three-month follow-up visit for all 56 patients in its pivotal clinical trial. This data collection is crucial as Envoy aims for a full PMA submission by early 2027 to potentially disrupt the existing cochlear implant market with its microphone-free technology.